INPART - a psycho-oncological intervention for partners of patients with haemato-oncological disease – study protocol

• Main Authors: Inga Lorenz, Daniela Bodschwinna, Nina Hallensleben, Hartmut Döhner, Dietger Niederwieser, Tanja Zimmermann, Anja Mehnert, Harald Gündel, Jochen Ernst, Klaus Hoenig
• Format: Article
• Language: English
• Published: BMC 2019-09-01
• Series: BMC Cancer
• Subjects: Psycho-oncology; Cancer; Group-intervention; Partner; Spouse; Depression
• Online Access: http://link.springer.com/article/10.1186/s12885-019-6094-2

Abstract Background Suffering from cancer confronts both the patient and their partner with a number of psychosocial challenges in various aspects of their life. These challenges may differentially impact on quality of life, coping ability and compliance to treatment. This especially holds true for haemato-oncological diseases. To date, psychological interventions have predominantly been developed for oncological patients however specific interventions for partners of haemato-oncological patients are rare. In this study we aim to conduct a psycho-oncological group-intervention for partners of patients with haemato-oncological diseases. The aim of the intervention is to significantly reduce symptoms of depression and anxiety in the partners and the patient, as well as enhancing dyadic coping. Methods The design of the INPART-study is an unblinded, randomised controlled trial with 2 treatment conditions (experimental and control) and assessments at baseline, 3 and 6 months. It will be conducted at three study centres: the university medical centre’s in Leipzig, Hannover and Ulm. The outcome criteria will be a reduction in depressive and anxiety symptoms as well as an improvement of dyadic coping. Discussion This trial shall provide information regarding the efficiency of a psycho-oncological intervention for partners of patients with haemato-oncological diseases and give references to the possible outcome in terms of dyadic coping and the reduction of mental strain. The study was supported by a grant from the German José Carreras Leukaemia Foundation. Trial registration ISRCTN16085028; 20/03/2019.